Key points are not available for this paper at this time.
The TP53 mutation, a prevalent tumor suppressor gene alteration, is linked to chemotherapy resistance, increased relapse rates and diminished overall survival (OS) in acute myeloid leukemia (AML) patients.
Zhu et al. (Fri,) studied this question.